Moderna is trading at $241.67, down 6.47%, as its decline coincides with broad-market and biotech pressure. - The Nasdaq is down 4.39% and the S&P 500 3.00% in the supplied market context. - The XBI is down 5.19%, consistent with the direction of Moderna’s move. - Moderna’s Q3 earnings are scheduled for November 6; available evidence does not establish them as the cause of the decline.